DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) common stock pursuant to Rule 144 for proceeds of approximately $942 million and, subject to the completion of the Rule 144 sale, a concurrent share repurchase by Cencora in the amount of approximately $50 million. Walgreens Boots Alliance’s ownership of Cencora’s common stock has decreased from approximately 15 percent to approximately 13 percent. Proceeds to ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 23, 2021. Cencora intends to use the net proceeds from the offering to redeem all of its 3.400% Sen ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 23, 2021. The offering is expected to close on February 7, 2024, subject to the satisfaction of customary closing cond ...

For the quarter ended December 2023, Cencora (COR) reported revenue of $72.25 billion, up 15% over the same period last year. EPS came in at $3.28, compared to $2.71 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $68.81 billion, representing a surprise of +5.00%. The company delivered an EPS surprise of +14.69%, with the consensus EPS estimate being $2.86.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

First quarter highlights & strategic overview Financial results 22.0% U.S. Healthcare Solutions segment operating income growth y/y Effective tax rate 23.0% 21.0% Cencora, Inc. First Quarter Fiscal 2024 Earnings Call January 31, 2024 In an effort to provide additional and useful information regarding Cencora's financial results and other financial information as determined by generally accepted accounting principles (GAAP), certain materials presented during this event include non-GAAP information. A reconc ...

Cencora, Inc. (NYSE:COR) Q1 2024 Earnings Conference Call January 31, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head IR & Treasury Steve Collis - Chairman, President & CEO Jim Cleary - EVP & CFO Conference Call Participants Stephanie Davis - Barclays Lisa Gill - JPMorgan Eric Percher - Nephron Research Daniel Grosslight - Citibank Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Erin Wright - Morgan Stanley Charles Rhyee - TD Cowen Eric Coldwell - Baird George Hill - Deutsche ...

Cencora, Inc. (COR) reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $3.28, which beat the Zacks Consensus Estimate of $2.86 by 14.7%. The bottom line also improved 21% year over year.GAAP EPS was $2.98, up 27.9% from that reported in the year-ago period.Revenue DetailsRevenues totaled $72.3 billion, up 15% year over year. The top line beat the Zacks Consensus Estimate by 5.1%.Segmental AnalysisU.S. Healthcare SolutionsRevenues in this segment totaled $65.2 billion, up 15.9% on a year ...

Cencora (COR) came out with quarterly earnings of $3.28 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $2.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.69%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $2.79 per share when it actually produced earnings of $2.86, delivering a surprise of 2.51%.Over the last four quarters, ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Cencora (COR) , which belongs to the Zacks Medical Services industry.This prescription drug distributor has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.84%.For the last reported quarter, Cencora came out with earnings of $2.86 pe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 CENCORA, INC. (Exact name of registrant as specified in its charter) Delaware 23-3079390 (State or other juri ...